Antibacterial and Antifungal Potential of Hermetia illucens Hemolymph Contained-Peptides
- PMID: 40773039
- DOI: 10.1007/s12602-025-10697-x
Antibacterial and Antifungal Potential of Hermetia illucens Hemolymph Contained-Peptides
Abstract
Antimicrobial peptides (AMPs) constitute a chemically and structurally heterogeneous family of molecules produced by a wide range of living organisms, including plants, fish, amphibians, mammals, and insects. Their expression is particularly high in hosts frequently exposed to microorganisms, where AMPs play a key role in innate immune responses. Insects represent one of the richest natural sources of AMPs. Over their long evolutionary history, they have developed a highly efficient immune system with AMPs playing a central role in defense against pathogens, enabling them to colonize various habitats. In recent years, interest in AMPs has significantly increased due to the emergence of antibiotic resistance, positioning these peptides as potential therapeutic alternatives for treating infections caused by multi-resistant pathogens. In this study, we investigated the antimicrobial activity of peptide fractions extracted from the hemolymph of Hermetia illucens larvae (Diptera, Stratiomyidae), an insect known for its high expression of AMPs. Larvae were injected separately with either Escherichia coli (Gram-negative) or Micrococcus flavus (Gram-positive), and hemolymph was collected 24 h post-infection, as well as from uninfected larvae. Antimicrobial activity was assessed through microbiological assays, including both agar diffusion tests and microdilution assays. Results demonstrated significant activity against pathogenic bacterial strains, including antibiotic-resistant ones. The Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) were determined for each experimental condition. MIC values ranged from 0.023 to 0.375 µg·µL⁻1, while MBC values ranged from 0.187 to 0.750 µg·µL⁻1, depending on the bacterial strain and the infection treatment group. These findings demonstrate the potential of H. illucens-derived AMPs as effective agents against Gram-positive and Gram-negative bacteria, including resistant strains, and support their further development as alternatives or adjuvants to conventional antibiotics.
Keywords: Hermetia illucens; Antimicrobial peptides; Black soldier fly; In vitro antibacterial activity; In vitro antifungal activity; Peptide fraction.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing Interests: The authors declare no competing interests.
Similar articles
-
Impact of Salmonella enteritidis Infection and Mechanical Stress on Antimicrobial Peptide Expression in Hermetia illucens.Insects. 2025 Jul 4;16(7):692. doi: 10.3390/insects16070692. Insects. 2025. PMID: 40725322 Free PMC article.
-
Bacteriological quality of fresh and processed black soldier fly Hermetia illucens larvae reared on chicken manure in Kitwe, Zambia.Microbiol Spectr. 2025 Aug 5;13(8):e0057024. doi: 10.1128/spectrum.00570-24. Epub 2025 Jun 20. Microbiol Spectr. 2025. PMID: 40539803 Free PMC article.
-
In Vitro Evaluation of the Antibacterial Activity of the Peptide Fractions Extracted from the Hemolymph of Hermetia illucens (Diptera: Stratiomyidae).Insects. 2023 May 15;14(5):464. doi: 10.3390/insects14050464. Insects. 2023. PMID: 37233092 Free PMC article.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3. PMID: 29271481 Free PMC article. Updated.
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
References
-
- Mohr KI (2016) History of antibiotics research. In: Stadler M, Dersch P (eds) How to overcome the antibiotic crisis. Curr Top Microbiol Immunol, vol 398. Springer, Cham, pp 237–272. https://doi.org/10.1007/82_2016_499 .
-
- Money NP (2024) Molds, mushrooms, and medicines: our lifelong relationship with fungi. Princeton Univ Press. https://doi.org/10.1515/9780691236315 - DOI
-
- Venturella G, Ferraro V, Cirlincione F, Gargano ML (2021) Medicinal mushrooms: bioactive compounds, use, and clinical trials. Int J Mol Sci 22:634. https://doi.org/10.3390/ijms22020634 - DOI - PubMed - PMC
-
- Bentley R (2000) Mycophenolic acid: a one hundred year odyssey from antibiotic to immunosuppressant. Chem Rev 100:3801–3826. https://doi.org/10.1021/cr990097b - DOI - PubMed
-
- Ligon BL (2004) Penicillin: its discovery and early development. Semin Pediatr Infect Dis 15:52–57. https://doi.org/10.1053/j.spid.2004.02.001 - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources